We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Selvita Sa | LSE:0RKT | London | Ordinary Share | PLSELVT00013 | SELVITA ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 57.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Chemicals & Chem Preps, Nec | 67.99M | -92.11M | -3.9841 | -14.31 | 1.32B |
From Apr 2019 to Apr 2024
KRAKOW, Poland, March 21, 2019 /PRNewswire/ -- Selvita (WSE: SLV), a clinical stage company engaged in the research and development of novel cancer therapies as well as provision of drug discovery and development services, today announced that it will report fourth quarter and year end 2018 financial results on Thursday, March 28, 2019, and provide a corporate update. Management will host a live video webcast at 10:00 a.m. CET/5:00 a.m. EST (Polish language).
The live webcast can be accessed live.selvita.com. An archived version of the webcast will be available following the call in the Investor Relations section of the Company's website at www.selvita.com.
Selvita will also host a press conference for investors and media in Warsaw, Poland.
About Selvita
Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division. Pipeline candidates apply diverse mechanisms directed at kinases, synthetic lethality pathways, immuno-oncology pathways and other cancer-related targets. SEL24/MEN1703 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. SEL120 is a CDK8 kinase inhibitor with potential for development in indications including hematological malignancies and solid tumors. Selvita is headquartered in Krakow with offices in the U.S. and U.K.
Contact:
Julia Balanova (investors)
+1-646-378-2936
jbalanova@troutgroup.com
Rich Allan (media)
+1-646-378-2958
rallan@troutgroup.com
Malgorzata Syjud (corporate)
+48-660-797-362
malgorzata.syjud@selvita.com
View original content:http://www.prnewswire.com/news-releases/selvita-to-host-conference-call-and-webcast-on-thursday-march-28-300816329.html
SOURCE Selvita
Copyright 2019 PR Newswire
1 Year Selvita Chart |
1 Month Selvita Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
